146 related articles for article (PubMed ID: 38491826)
1. Exploring the relation of active surveillance schedules and prostate cancer mortality.
Yang Z; Heijnsdijk EAM; Newcomb LF; Rizopoulos D; Erler NS
Cancer Med; 2024 Mar; 13(5):e6977. PubMed ID: 38491826
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts.
Lange JM; Laviana AA; Penson DF; Lin DW; Bill-Axelson A; Carlsson SV; Newcomb LF; Trock BJ; Carter HB; Carroll PR; Cooperberg MR; Cowan JE; Klotz LH; Etzioni RB
Cancer; 2020 Feb; 126(3):583-592. PubMed ID: 31639200
[TBL] [Abstract][Full Text] [Related]
3. Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers.
Bokhorst LP; Alberts AR; Rannikko A; Valdagni R; Pickles T; Kakehi Y; Bangma CH; Roobol MJ;
Eur Urol; 2015 Nov; 68(5):814-21. PubMed ID: 26138043
[TBL] [Abstract][Full Text] [Related]
4. Regular transition zone biopsy during active surveillance for prostate cancer may improve detection of pathological progression.
Wong LM; Toi A; Van der Kwast T; Trottier G; Alibhai SM; Timilshina N; Evans A; Zlotta A; Fleshner N; Finelli A
J Urol; 2014 Oct; 192(4):1088-93. PubMed ID: 24742593
[TBL] [Abstract][Full Text] [Related]
5. Personalized Decision Making for Biopsies in Prostate Cancer Active Surveillance Programs.
Tomer A; Rizopoulos D; Nieboer D; Drost FJ; Roobol MJ; Steyerberg EW
Med Decis Making; 2019 Jul; 39(5):499-508. PubMed ID: 31319751
[No Abstract] [Full Text] [Related]
6. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
[TBL] [Abstract][Full Text] [Related]
7. Personalised biopsy schedules based on risk of Gleason upgrading for patients with low-risk prostate cancer on active surveillance.
Tomer A; Nieboer D; Roobol MJ; Bjartell A; Steyerberg EW; Rizopoulos D;
BJU Int; 2021 Jan; 127(1):96-107. PubMed ID: 32531869
[TBL] [Abstract][Full Text] [Related]
8. PCASTt/SPCG-17-a randomised trial of active surveillance in prostate cancer: rationale and design.
Ahlberg MS; Adami HO; Beckmann K; Bertilsson H; Bratt O; Cahill D; Egevad L; Garmo H; Holmberg L; Johansson E; Rannikko A; Van Hemelrijck M; Jäderling F; Wassberg C; Åberg UWN; Bill-Axelson A
BMJ Open; 2019 Aug; 9(8):e027860. PubMed ID: 31444180
[TBL] [Abstract][Full Text] [Related]
9. The Clinical Significance of Multiple Negative Surveillance Prostate Biopsies for Men on Active Surveillance-Does Cancer Vanish or Simply Hide?
Chu CE; Cowan JE; Fasulo V; Washington SL; de la Calle C; Shoemaker J; Carroll PR
J Urol; 2021 Jan; 205(1):109-114. PubMed ID: 33198555
[TBL] [Abstract][Full Text] [Related]
10. Estimating the risks and benefits of active surveillance protocols for prostate cancer: a microsimulation study.
de Carvalho TM; Heijnsdijk EA; de Koning HJ
BJU Int; 2017 Apr; 119(4):560-566. PubMed ID: 27222299
[TBL] [Abstract][Full Text] [Related]
11. Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database.
Beckmann KR; Bangma CH; Helleman J; Bjartell A; Carroll PR; Morgan T; Nieboer D; Santaolalla A; Trock BJ; Valdagni R; Roobol MJ;
Prostate; 2022 May; 82(7):876-879. PubMed ID: 35254666
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Outcomes after Deferred Radical Prostatectomy in Men Initially Treated with Active Surveillance.
Godtman RA; Schafferer M; Pihl CG; Stranne J; Hugosson J
J Urol; 2018 Oct; 200(4):779-785. PubMed ID: 29730198
[TBL] [Abstract][Full Text] [Related]
13. Indications for intervention during active surveillance of prostate cancer: a comparison of the Johns Hopkins and Prostate Cancer Research International Active Surveillance (PRIAS) protocols.
Kates M; Tosoian JJ; Trock BJ; Feng Z; Carter HB; Partin AW
BJU Int; 2015 Feb; 115(2):216-22. PubMed ID: 24904995
[TBL] [Abstract][Full Text] [Related]
14. The Magnetic Resonance Imaging in Active Surveillance (MRIAS) Trial: Use of Baseline Multiparametric Magnetic Resonance Imaging and Saturation Biopsy to Reduce the Frequency of Surveillance Prostate Biopsies.
Amin A; Scheltema MJ; Shnier R; Blazevski A; Moses D; Cusick T; Siriwardena A; Yuen B; van Leeuwen PJ; Haynes AM; Matthews J; Brenner P; O'Neill G; Yuen C; Delprado W; Stricker P; Thompson J
J Urol; 2020 May; 203(5):910-917. PubMed ID: 31825297
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of Active Surveillance after Initial Surveillance Prostate Biopsy.
Kovac E; Lieser G; Elshafei A; Jones JS; Klein EA; Stephenson AJ
J Urol; 2017 Jan; 197(1):84-89. PubMed ID: 27449260
[TBL] [Abstract][Full Text] [Related]
16. Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts.
Inoue LYT; Lin DW; Newcomb LF; Leonardson AS; Ankerst D; Gulati R; Carter HB; Trock BJ; Carroll PR; Cooperberg MR; Cowan JE; Klotz LH; Mamedov A; Penson DF; Etzioni R
Ann Intern Med; 2018 Jan; 168(1):1-9. PubMed ID: 29181514
[TBL] [Abstract][Full Text] [Related]
17. Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study.
Kearns JT; Faino AV; Newcomb LF; Brooks JD; Carroll PR; Dash A; Ellis WJ; Fabrizio M; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Zheng Y; Lin DW
Eur Urol; 2018 May; 73(5):706-712. PubMed ID: 29433973
[TBL] [Abstract][Full Text] [Related]
18. Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up.
Hamoen EHJ; Hoeks CMA; Somford DM; van Oort IM; Vergunst H; Oddens JR; Smits GA; Bokhorst LP; Witjes JA; Rovers MM; Hulsbergen-van de Kaa CA; Barentsz JO
Eur Urol Focus; 2019 May; 5(3):407-415. PubMed ID: 29331622
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of Scheduled vs For-Cause Biopsy Regimens for Prostate Cancer Active Surveillance.
Al-Tartir T; Murekeyisoni C; Attwood K; Badkhshan S; Mehedint D; Safwat M; Guru K; Mohler JL; Kauffman EC
J Urol; 2016 Oct; 196(4):1061-8. PubMed ID: 27157375
[TBL] [Abstract][Full Text] [Related]
20. Using Competing Risk of Mortality to Inform the Transition from Prostate Cancer Active Surveillance to Watchful Waiting.
Huang MM; Alam R; Gabrielson AT; Su ZT; Kassiri B; Fletcher SA; Biles MJ; Patel HD; Pavlovich CP; Schwen ZR
Eur Urol Focus; 2022 Sep; 8(5):1141-1150. PubMed ID: 34344628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]